NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

IMRX

Immuneering Corp

Jul 03 • 04:00PM ET

3.45

Dollar change -0.14
Percentage change -3.90	%

Healthcare • Biotechnology • USA • NASD

Peers: RCKT SRRK RNA SYRS STRO CUE MGTX CABA UBX ADAP

| Held by: VTI VXF IWC CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.97	Insider Own	28.23%	Shs Outstand	35.99M	Perf Week	8.15%
Market Cap	124.15M	Forward P/E	-	EPS next Y	-1.58	Insider Trans	1.21%	Shs Float	25.83M	Perf Month	76.02%
Enterprise Value	92.36M	PEG	-	EPS next Q	-0.42	Inst Own	12.50%	Short Float	3.46%	Perf Quarter	121.15%
Income	-61.77M	P/S	-	EPS this Y	15.16%	Inst Trans	4.53%	Short Ratio	0.83	Perf Half Y	53.33%
Sales	0.00M	P/B	2.97	EPS next Y	8.46%	ROA	-89.10%	Short Interest	0.89M	Perf YTD	56.82%
Book/sh	1.16	P/C	3.46	EPS next 5Y	8.73%	ROE	-102.48%	52W High	3.87 -10.93%	Perf Year	194.87%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	-16.91% -46.45%	ROIC	-135.55%	52W Low	1.00 245.00%	Perf 3Y	-31.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	13.37% 16.26%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.95%	Oper. Margin	-	ATR (14)	0.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.48	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	67.77	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	7.48	EPS Q/Q	13.07%	SMA20	30.21%	Beta	0.37	Target Price	11.42
Payout	-	Debt/Eq	0.10	Sales Q/Q	-	SMA50	78.81%	Rel Volume	0.85	Prev Close	3.59
Employees	66	LT Debt/Eq	0.09	Earnings	May 05 AMC	SMA200	77.62%	Avg Volume	1.07M	Price	3.45
IPO	Jul 30, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	20.26% -	Trades		Volume	907,540	Change	-3.90%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-24	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Mar-15-24	Reiterated	Needham	Buy	$20 → $15
Mar-15-24	Downgrade	TD Cowen	Outperform → Market Perform
Mar-15-24	Downgrade	Jefferies	Buy → Hold	$16 → $3
Dec-01-23	Initiated	Needham	Buy	$20
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $14
Apr-19-23	Upgrade	Mizuho	Neutral → Buy	$10 → $20
Mar-30-23	Initiated	Mizuho	Neutral	$10
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$12 → $5
Jul-08-22	Initiated	Chardan Capital Markets	Buy	$18
Apr-01-22	Initiated	Oppenheimer	Outperform	$25
Jan-07-22	Initiated	Piper Sandler	Overweight	$41

Show Previous Ratings

Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -7.58%
Jun-17-25 06:00AM	Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients (GlobeNewswire) -23.21%
Jun-16-25 08:00AM	Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025 (GlobeNewswire) +24.74%
May-29-25 08:00AM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.83%
May-05-25 04:05PM	Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
08:00AM	Loading…
Apr-02-25 08:00AM	Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-21-25 04:30PM	Immuneering Corporation Announces Grant of Inducement Award (GlobeNewswire) +9.09%
Mar-20-25 04:05PM	Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
07:12AM	Immuneering names Igor Matushansky as chief medical officer (SeekingAlpha)
07:00AM	Immuneering Names Dr. Igor Matushansky as Chief Medical Officer (GlobeNewswire)
Feb-06-25 07:00AM	Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo (cemiplimab) (GlobeNewswire)
Feb-03-25 04:05PM	Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-13-25 08:00AM	Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer (GlobeNewswire)
Jan-07-25 09:28AM	Why Is Immuneering Stock Trading Higher On Tuesday? (Benzinga)
07:00AM	Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms (GlobeNewswire)
10:49AM	Loading…
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +10.00%
Dec-19-24 08:00AM	Immuneering Launches Pancreatic Cancer Advisory Board (GlobeNewswire) +13.58%
Dec-17-24 08:00AM	Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025 (GlobeNewswire)
Dec-13-24 02:10PM	Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? (Benzinga) -17.01%
Dec-12-24 08:00AM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma (GlobeNewswire) -7.94%
Nov-27-24 08:00AM	Immuneering to Present at the Piper Sandler 36 Annual Healthcare Conference (GlobeNewswire)
Nov-13-24 04:05PM	Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -6.56% +13.45%
Oct-15-24 08:00AM	Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer (GlobeNewswire) +15.50%
Sep-13-24 08:14AM	Why Is Nanocap Immuneering Stock Trading Higher On Friday? (Benzinga) +41.26%
Sep-12-24 04:05PM	Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients (GlobeNewswire) +10.85%
Aug-29-24 08:00AM	Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-06-24 04:05PM	Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -8.06%
Jul-31-24 04:05PM	Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer (GlobeNewswire) +19.47%
May-29-24 04:05PM	Immuneering to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire)
10:55PM	Loading…
May-07-24 10:55PM	IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024 (InvestorPlace) -5.45%
04:05PM	Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
May-06-24 04:30PM	Immuneering Recognizes Melanoma Awareness Month (GlobeNewswire)
Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Immuneering to Participate in the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Mar-03-24 07:01PM	Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-01-24 08:00AM	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 08:00AM	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer (GlobeNewswire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +8.00%
Feb-01-24 08:00AM	Immuneering Announces Participation in February Investor Conferences (GlobeNewswire)
Dec-12-23 08:00AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire) -7.11%
Nov-20-23 04:05PM	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +25.45%
Nov-09-23 04:05PM	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -11.86%
Oct-12-23 04:05PM	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference (GlobeNewswire) -6.65%
Oct-04-23 04:05PM	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-23 08:00AM	Immuneering to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire)
Aug-03-23 04:05PM	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-02-23 06:09AM	Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership (Simply Wall St.)
Jul-05-23 09:55AM	Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet (Zacks)
Jun-05-23 08:00AM	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors (GlobeNewswire)
May-30-23 08:00AM	Immuneering to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.86%
May-04-23 07:25PM	Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.75%
04:05PM	Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-18-23 09:24AM	Immuneering Announces $30 Million Underwritten Offering (GlobeNewswire) +9.60%
09:00AM	Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline (GlobeNewswire)
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-12-23 04:05PM	Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-11-23 03:56AM	Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains? (Zacks) +5.78%
Apr-05-23 08:00AM	Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-28-23 08:00AM	Immuneering Appoints Harold E. Brakewood as Chief Business Officer (GlobeNewswire) -7.40%
Mar-27-23 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade (Zacks)
Mar-24-23 01:25PM	Why Shares of Immuneering Jumped This Week (Motley Fool)
Mar-23-23 06:18AM	Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-14-23 04:30PM	Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) +5.62% -8.05%
Mar-09-23 09:55AM	Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect? (Zacks) +5.47%
Mar-08-23 07:14AM	Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Call Transcript (Insider Monkey) +22.87%
Mar-06-23 05:45PM	Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +6.17%
04:05PM	Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-23 06:30PM	Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity (GlobeNewswire)
Feb-28-23 08:00AM	Immuneering Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-27-23 08:00AM	Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-05-23 07:18AM	Immuneering Corporation (NASDAQ:IMRX) insiders, who hold 31% of the firm would be disappointed by the recent pullback (Simply Wall St.)
Jan-31-23 06:50AM	Immuneering To Present at Guggenheim 2023 Oncology Conference (GlobeNewswire)
Nov-28-22 06:50AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (GlobeNewswire)
Nov-16-22 06:35AM	Immuneering Third Quarter 2022 Earnings: Revenues Disappoint (Simply Wall St.)
Nov-10-22 10:15AM	Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
09:00AM	Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
09:00AM	Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC (GlobeNewswire)
Nov-03-22 06:50AM	Immuneering Announces Participation in November Investor Conferences (GlobeNewswire) -12.80%
Oct-20-22 06:50AM	Immuneering Appoints Leah R. Neufeld as Chief People Officer (GlobeNewswire)
Oct-05-22 08:05AM	Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -5.80%
Sep-30-22 12:00PM	What Makes Immuneering Corporation (IMRX) a New Buy Stock (Zacks) +9.15%
06:50AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations (GlobeNewswire)
Sep-12-22 09:55AM	Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High? (Zacks) +10.82%
Sep-05-22 10:21AM	Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 (Zacks)
Sep-02-22 08:09AM	Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations (GlobeNewswire) +7.05%
Aug-25-22 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade (Zacks) -7.35%
06:50AM	Immuneering Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-10-22 05:55PM	Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-08-22 12:24PM	Immuneering (NASDAQ:IMRX) shareholders have endured a 77% loss from investing in the stock a year ago (Simply Wall St.) +11.25%
Jul-22-22 10:01AM	Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock? (Zacks)

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 02 '25	Buy	3.53	7,015	24,792	2,312,852	Jul 03 09:12 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jul 01 '25	Buy	3.38	2,985	10,087	2,305,837	Jul 03 09:12 AM
Schall Thomas J.	Director	Jun 27 '25	Buy	3.66	9,500	34,788	52,885	Jun 30 09:09 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 20 '25	Buy	2.70	7,415	20,020	353,311	Jun 24 09:01 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Jun 23 '25	Buy	2.43	6,007	14,596	359,318	Jun 24 09:01 AM
Brakewood Harold Eugene	Chief Business Officer	Jun 20 '25	Buy	2.53	1,900	4,804	5,800	Jun 24 08:52 AM
Feinberg Peter	Director	Jun 18 '25	Buy	2.53	25,000	63,188	136,766	Jun 23 09:09 AM
Zeskind Benjamin J.	PRESIDENT AND CEO	Jun 18 '25	Buy	2.39	21,000	50,144	2,302,852	Jun 20 09:09 AM
Schall Thomas J.	Director	Jun 17 '25	Buy	2.21	40,485	89,278	43,385	Jun 18 09:11 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMRX

Immuneering Corp

Upgrade your FINVIZ experience